Share

Quick Heal Technologies Limited Stocks

163.28Last Updated 13.04.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

₹ 94.86M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
163.28
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Quick Heal Technologies Limited provides security software products and solutions to consumers, small businesses, government establishments, and corporate houses in India and internationally. The company operates through Retail, Enterprise and Government, and Mobile segments. Its products portfolio includes GoDeep.AI, a malware hunting engine; Seqrite Hawk, a cybersecurity solution; and Hawk Eye, a cloud-based platform for enterprise grade centralized security management. The company also offers technical and after-sales support services. It sells its products through a network of service providers, system integrators, resellers, and distributors. The company offers its products under Seqrite brand. Quick Heal Technologies Limited was incorporated in 1995 and is based in Pune, India.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks